Biological Markers for Chemotherapy Induced toxicities in Patients with Malignancy
Rasha Adel Fathy Thabet;
Abstract
This prospective study was conducted on 30 patients with cancer during the period from February 2011 to February 2013. Patients were recruited from the in-patients' department and oncology clinic at the children's hospital, Ain Shams University and National Cancer Institute. They were 11 females and 19 males with a mean of age 7.4±4.3 years.
Patients were divided according to the type of cancer into 22 patients with ALL, 3 patients with AML, 4 patients with NHL and only one patient with NHL. The patients were compared to a control group of 30 healthy children of the same age group.
Patients were assessed before initiation of therapy. First follow up was done after two month of chemotherapy (i.e. patients with ALL received consolidation therapy while patients with NHL received about two cycles of chemotherapy).The second follow up was done after 6 month of chemotherapy.
The patient data included sociodemographic data, diagnosis data, treatment data and data of complications.
Patients were examined initially and during each follow up and it included:
- General examination which includes: anthropometric measurements, oral, anal, skin, and lymph node examinations.
- Systemic examination especially: Abdominal, cardiovascular, chest and neurological examination.
Laboratory investigations which were taken included: CBC, liver function tests (ALT, AST, total bilirubin),kidney functions (s.creatinine, BUN, creatinine clearance), Randam blood sugar, triglyceride, cholesterol, cardiac troponin and glucagon like peptide 2. These laboratory investigations were taken before therapy, after 2 month and after 6 months from the start of chemotherapy.
Data collected from the patients was compared with the control and with each other. Laboratory data was compared with the cumulative doses of the chemotherapeutic agent during each follow up.
When we compared the patients with the controls at presentation we found that there was a significantly lower BMI in patients compared to controls at presentation; meanwhile there was no significant difference as regard weight, height, standardized weight and height.
Patients were divided according to the type of cancer into 22 patients with ALL, 3 patients with AML, 4 patients with NHL and only one patient with NHL. The patients were compared to a control group of 30 healthy children of the same age group.
Patients were assessed before initiation of therapy. First follow up was done after two month of chemotherapy (i.e. patients with ALL received consolidation therapy while patients with NHL received about two cycles of chemotherapy).The second follow up was done after 6 month of chemotherapy.
The patient data included sociodemographic data, diagnosis data, treatment data and data of complications.
Patients were examined initially and during each follow up and it included:
- General examination which includes: anthropometric measurements, oral, anal, skin, and lymph node examinations.
- Systemic examination especially: Abdominal, cardiovascular, chest and neurological examination.
Laboratory investigations which were taken included: CBC, liver function tests (ALT, AST, total bilirubin),kidney functions (s.creatinine, BUN, creatinine clearance), Randam blood sugar, triglyceride, cholesterol, cardiac troponin and glucagon like peptide 2. These laboratory investigations were taken before therapy, after 2 month and after 6 months from the start of chemotherapy.
Data collected from the patients was compared with the control and with each other. Laboratory data was compared with the cumulative doses of the chemotherapeutic agent during each follow up.
When we compared the patients with the controls at presentation we found that there was a significantly lower BMI in patients compared to controls at presentation; meanwhile there was no significant difference as regard weight, height, standardized weight and height.
Other data
| Title | Biological Markers for Chemotherapy Induced toxicities in Patients with Malignancy | Other Titles | العلامات البيولوجية للمضاعفات الناتجة عن العلاج الكيميائي لمرضي السرطان | Authors | Rasha Adel Fathy Thabet | Issue Date | 2014 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.